The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ICML 2019 | Comments on the addition of lenalidomide to R-CHOP in two studies

Jun 26, 2019
Share:

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Marek Trněný, Charles University General Hospital, Prague, CZ, about the impact of the total metabolic tumor volume on the identification of patients who failed treatment while refractory.

He also discusses two randomised trials that investigated lenalidomide and R-CHOP, mentioning that the phase III study failed to show benefits, while results of the phase II trial were positive.

ICML 2019 | Comments on the addition of lenalidomide to R-CHOP in two studies

Share: